Journal · Updated 2026-08-11
Ivim Health Review 2026: The $75 Membership Model, All-In at $149 Sema / $278 Tirz
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
Ivim Health is a membership program whose two molecules land in very different places. Semaglutide at roughly one forty-nine all-in — the seventy-five-dollar membership already counted — is quietly competitive: twenty dollars over bmiMD's floor, level with the one-forty-nine cluster, under Henry's one seventy-nine, with provider care bundled. Tirzepatide at roughly two seventy-eight all-in is not: it matches Mochi's price without Mochi's programming depth, a hundred-plus over the flat-rate tier. Status: provider-stated on our records. The structural read: Ivim is a semaglutide value wearing a mid-tier tirzepatide price, and the membership mechanics — what the seventy-five dollars buys, and what leaving costs — are the review's live questions.
The split personality, priced
Membership models live or die by the all-in figure, and Ivim's two all-ins tell opposite stories. On semaglutide, one forty-nine buys membership-included care at a price the medication-only programs barely beat — the twenty-dollar gap to bmiMD is the cheapest bundled-care premium in the market, and for a buyer who values a standing provider relationship it's arguably the segment's best quiet deal. On tirzepatide, the same structure prices at two seventy-eight against NexLife's one sixty-nine and the one seventy-nine flat tier — a ninety-nine-plus premium buying the same membership that cost twenty on the other molecule, which is the fee-exclusion arithmetic from the teaser index doing its usual work. The molecule you're on effectively decides the verdict before any other factor does.
The membership questions, and the verdict
Three, in writing, at intake: What exactly does the seventy-five dollars buy monthly — visit cadence, messaging access, labs or not — since the value case rests entirely on the answer; can the membership pause or must it cancel during medication breaks (the regain economics make breaks and returns a real pattern); and which pharmacy fills the prescription — unnamed publicly, standard verification applies. Then the placement: semaglutide buyers who want bundled care land here well at one forty-nine; tirzepatide buyers pay a structural premium the flat-rate tier doesn't charge, and unless the membership's contents survive the first question above with unusual strength, the one sixty-nine-to-one seventy-nine programs are the arithmetic's answer. A program can be two verdicts at once; Ivim is the market's clearest case of it.
Questions people ask
How much does Ivim Health cost all-in?
About $149 a month for semaglutide and $278 for tirzepatide, with the mandatory $75 membership already included in both figures (provider-stated status on our records). The membership makes all-in the only comparable number — and it lands the two molecules in very different competitive positions.
Is Ivim a good deal for semaglutide?
Quietly, yes: $149 all-in sits $20 over bmiMD's $129 floor with provider care bundled — the cheapest membership-included semaglutide we track, level with the $149 cluster and under Henry's $179. Confirm what the membership includes and the pharmacy name at intake; both are the deal's substance.
Why is Ivim's tirzepatide considered expensive?
$278 all-in matches Mochi's price without the same programming depth, and runs $99–$109 over the flat-rate tier (NexLife $169 promotional, Henry/bmiMD $179). The same $75 membership that costs a $20 premium on semaglutide costs a ~$100 premium on tirzepatide — the fee-exclusion arithmetic working against the pricier molecule.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.